oxymetazoline has been researched along with Dermatitis in 3 studies
Oxymetazoline: A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)
oxymetazoline : A member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion.
Dermatitis: Any inflammation of the skin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "18) -hours SSA success rate after oxymetazoline treatment for rosacea is significantly higher than that of vehicle." | 9.41 | Efficacy and safety of oxymetazoline for the treatment of rosacea: A meta-analysis. ( Cao, Y; Fu, H; Li, Y; Liu, F; Luo, H; Tao, M; Wang, H; Zhou, Q, 2023) |
| " Safety assessments included treatment-emergent adverse events (TEAEs) and posttreatment worsening of erythema (composite CEA/SSA increase of 1-grade severity from baseline; rebound effect)." | 6.87 | Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial. ( Ahluwalia, G; Berk, DR; Cook-Bolden, FE; Draelos, ZD; DuBois, J; Grande, K; Kircik, LH; Weng, E; Werschler, P, 2018) |
| "18) -hours SSA success rate after oxymetazoline treatment for rosacea is significantly higher than that of vehicle." | 5.41 | Efficacy and safety of oxymetazoline for the treatment of rosacea: A meta-analysis. ( Cao, Y; Fu, H; Li, Y; Liu, F; Luo, H; Tao, M; Wang, H; Zhou, Q, 2023) |
| "Topical oxymetazoline and brimonidine are the only medications approved for treating persistent facial erythema of rosacea." | 5.12 | Difference in vasoconstrictors: oxymetazoline vs. brimonidine. ( Cline, A; Feldman, SR; Okwundu, N, 2021) |
| " Safety assessments included treatment-emergent adverse events (TEAEs) and posttreatment worsening of erythema (composite CEA/SSA increase of 1-grade severity from baseline; rebound effect)." | 2.87 | Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial. ( Ahluwalia, G; Berk, DR; Cook-Bolden, FE; Draelos, ZD; DuBois, J; Grande, K; Kircik, LH; Weng, E; Werschler, P, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, F | 1 |
| Zhou, Q | 1 |
| Wang, H | 1 |
| Fu, H | 1 |
| Li, Y | 1 |
| Tao, M | 1 |
| Luo, H | 1 |
| Cao, Y | 1 |
| Kircik, LH | 1 |
| DuBois, J | 1 |
| Draelos, ZD | 1 |
| Werschler, P | 1 |
| Grande, K | 1 |
| Cook-Bolden, FE | 1 |
| Weng, E | 1 |
| Berk, DR | 1 |
| Ahluwalia, G | 1 |
| Okwundu, N | 1 |
| Cline, A | 1 |
| Feldman, SR | 1 |
2 reviews available for oxymetazoline and Dermatitis
| Article | Year |
|---|---|
Efficacy and safety of oxymetazoline for the treatment of rosacea: A meta-analysis.
Topics: Dermatitis; Humans; Oxymetazoline; Randomized Controlled Trials as Topic; Rosacea; Skin Cream; Treat | 2023 |
Difference in vasoconstrictors: oxymetazoline vs. brimonidine.
Topics: Administration, Topical; Brimonidine Tartrate; Clinical Trials as Topic; Dermatitis; Erythema; Human | 2021 |
1 trial available for oxymetazoline and Dermatitis
| Article | Year |
|---|---|
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Dermatitis; Double-Blind Method; Erythema | 2018 |